Medrx Co

Medrx Co Operating Cash Flow

The Operating Cash Flow of Medrx Co (4586.T) as of Oct 16, 2026 is -888.11 M JPY. In the previous year, Operating Cash Flow was -803.00 M JPY — a change of 10.60% (lower).

Operating Cash Flow

-888.11 MJPY

YoY

10.60%

Last updated:

Operating Cash Flow of Medrx Co is 2025 -888.11 M JPY. Operating Cash Flow of Medrx Co was 2024 -803.00 M JPY. It decreases by 10.60% lower compared to the previous year.

The Medrx Co Operating Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Cash Flow
Date
Operating Cash Flow
Jan 1, 2018
-1.26 B JPY
Jan 1, 2019
-1.55 B JPY
Jan 1, 2020
-985.35 M JPY
Jan 1, 2021
-923.69 M JPY
Jan 1, 2022
-1.07 B JPY
Jan 1, 2023
-913.00 M JPY
Jan 1, 2024
-803.00 M JPY
Jan 1, 2025
-888.11 M JPY
The Medrx Co Operating Cash Flow history
YEAROperating Cash FlowYoY
-888.11 MJPY+10.60%
-803.00 MJPY-12.05%
-913.00 MJPY-14.93%
-1.07 BJPY+16.20%
-923.69 MJPY-6.26%
-985.35 MJPY-36.30%
-1.55 BJPY+22.69%
-1.26 BJPY+47.58%
-854.32 MJPY-29.69%
-1.22 BJPY+53.98%
-789.06 MJPY-15.32%
-931.81 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co Ltd is a pharmaceutical company based in Higashikagawa-shi, Japan, operating within the Health Care sector. The company has 22 employees and went public on February 13, 2013, with its ticker listed as 4586.T on the Tokyo Stock Exchange. Medrx focuses on pharmaceutical drug development utilizing transdermal absorption technology. The company's website is www.medrx.co.jp. Medrx develops new medicines using percutaneous absorption formulation technology, specifically employing ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). These technologies leverage ionic liquid characteristics and nano colloidization to enhance drug efficacy, minimize side effects, and provide alternative administration methods for patients who cannot take medications orally. The company aims to create medicines with innovative value by addressing challenges such as patient compliance and delivery methods for difficult-to-administer drugs. Medrx is headquartered in Higashikagawa-shi, Kagawa Prefecture, and maintains a small operational scale with a dedicated team of 22 full-time employees. The company's business model centers on developing pharmaceuticals that improve patient outcomes through advanced transdermal delivery systems, targeting specific medical needs where traditional oral administration is impractical or ineffective. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Operating Cash Flow of Medrx Co is -888.11 M JPY in 2025.

Operating Cash Flow of Medrx Co changed from -803.00 M JPY to -888.11 M JPY, representing a 10.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow measures the cash generated from core business operations. It is a pure measure of a company's ability to generate cash.

Operating Cash Flow's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Operating Cash Flow's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Medrx Co

All Key Metrics — Medrx Co